Table 1.
Baseline characteristics of 101 lamin A/C genotype patients
| Clinical data | Total, n = 101 | Younger tertile, n = 34 | Middle tertile, n = 34 | Older tertile, n = 33 | P |
|---|---|---|---|---|---|
| Follow-up time (years) | 4.4 (2.5–6.6) | 6.1 (3.4–9.6) | 2.6 (1.7–4.6) | 2.5 (2.5–3.0) | <0.01 |
| Clinical visits, n | 5 (3–9) | 6 (4–10) | 6 (4–9) | 4 (3–7) | 0.11 |
| Age at inclusion (years) | 44 (29–54) | 22 (15–29) | 44 (38–47) | 57 (55–60) | <0.001 |
| Female sex, n (%) | 50 (50) | 17 (50) | 19 (56) | 14 (42) | 0.57 |
| Proband, n (%) | 39 (39) | 3 (9) | 15 (44) | 21 (64) | <0.001 |
| Families | 33 | 18 | 20 | 15 | NA |
| NYHA I, n (%) | 70 (69) | 30 (88) | 27 (79) | 13 (41) | <0.001 |
| NYHA II, n (%) | 15 (15) | 2 (6) | 4 (12) | 9 (28) | 0.045 |
| NYHA III, n (%) | 12 (13) | 1 (3) | 3 (9) | 8 (25) | 0.03 |
| NYHA IV, n (%) | 3 (3) | 1 (3) | 0 (0) | 2 (6) | 0.31 |
| Electrophysiological | |||||
| AV-block I, n (%) | 14 (14) | 3 (10) | 7 (23) | 4 (14) | 0.39 |
| AV-block II, n (%) | 3 (3) | 0 (0) | 1 (3) | 2 (7) | 0.32 |
| AV-block III, n (%) | 27 (27) | 0 (0) | 9 (30) | 18 (62) | <0.001 |
| Atrial fibrillation, n (%) | 45 (45) | 4 (12) | 16 (47) | 25 (78) | <0.001 |
| Pacemaker, n (%) | 15 (15) | 0 (0) | 7 (20) | 8 (24) | <0.01 |
| ICD, n (%) | 2 (2) | 0 (0) | 0 (0) | 2 (6) | 0.10 |
| CRT-D, n (%) | 9 (9) | 0 (0) | 0 (0) | 9 (28) | <0.001 |
| Medication | |||||
| ACE inhibitor, n (%) | 19 (19) | 0 (0) | 5 (15) | 14 (43) | <0.001 |
| β-Blocker, n (%) | 23 (23) | 1 (3) | 8 (24) | 14 (44) | <0.001 |
| MCRA, n (%) | 6 (6) | 0 (0) | 1 (3) | 5 (16) | 0.01 |
| Comorbidities | |||||
| Hypertension, n (%) | 3 (3) | 0 (0) | 0 (0) | 3 (9) | 0.32 |
| Coronary artery disease, n (%) | 3 (3) | 0 (0) | 0 (0) | 3 (9) | 0.03 |
| Stroke, n (%) | 5 (5) | 1 (3) | 0 (0) | 4 (13) | 0.04 |
| COPD, n (%) | 1 (1) | 0 (0) | 1 (3) | 0 (0) | 0.65 |
| Diabetes, n (%) | 5 (5) | 1 (3) | 1 (3) | 3 (9) | 0.44 |
Values are mean ± standard deviation, median (IQR), or frequency (%). P-values by one-way ANOVA, Kruskal–Wallis test, or Fisher’s exact test as appropriate.
ACE inhibitor; angiotensin converting enzyme inhibitor, AV-block; atrioventricular block, BMI; body mass index, COPD; chronic obstructive pulmonary disease, CRT-D; cardiac resynchronization therapy defibrillator, DCM; dilated cardiomyopathy, MCRA; mineral corticoid receptor antagonist, NSVT; non-sustained ventricular tachycardia, NYHA; New York Heart Association functional class, VA; ventricular arrhythmia.